Core Insights - Autonomix Medical, Inc. has been granted a new patent, strengthening its position in a multi-billion-dollar market for medical devices targeting cardiovascular, renal, and other high-burden diseases [1][2] Patent and Technology - The newly issued Patent No. 3,697,298 ('298 patent) relates to a medical device that captures and processes physiological signals for real-time monitoring, applicable in various fields including coronary artery mapping and neurotherapy [1][3] - The '298 patent enhances the company's competitive edge by protecting its proprietary technology, which is expected to create diverse revenue streams and expand its global presence [2][3] Technology Platform - Autonomix's technology platform features a catheter-based microchip sensing array that can detect neural signals with greater sensitivity than existing technologies, enabling precision-guided treatment for conditions like chronic pain and hypertension [4][6] - The system includes distributed signal acquisition modules that improve data integrity during neural mapping, with key elements such as miniaturization and noise reduction [3][4] Development Focus - The company is initially focusing on developing its technology for treating pancreatic cancer, a condition associated with severe pain and lacking reliable treatment options [7] - The technology has the potential to address a wide range of indications, including cardiology and chronic pain management, across various disease categories [7]